Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

NCT05552937 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

DLBCL

Interventions

DRUG: Tafasitamab and Lenalidomide

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.